Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study)

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/27409

Title:	Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study)
Authors:	Schippling, S. Arnold, D. Barnett, M. Comi, G. Laganke, C. Rovira, A. Traboulsee, A. Melanson, M. Daizadeh, N. Nakamura, K. VAN WIJMEERSCH, Bart Pelletier, D.
Issue Date:	2018
Publisher:	WILEY
Source:	EUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 527-527 (Art N° EPR3087)
Notes:	[Schippling, S.] Univ Hosp Zurich, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Arnold, D.] NeuroRx Res, Montreal, PQ, Canada. [Arnold, D.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Barnett, M.] Univ Sydney, Sydney, NSW, Australia. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Laganke, C.] North Cent Neurol Associates, Cullman, AL USA. [Rovira, A.] Vall dHebron Univ Hosp, Barcelona, Spain. [Traboulsee, A.] Univ British Columbia, Vancouver, BC, Canada. [Melanson, M.; Daizadeh, N.; OBOTC-MIC Investigator; Topaz Investigator] Sanofi, Cambridge, MA USA. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [van Wijmeersch, B.] Hasselt Univ, Hasselt, Belgium. [Pelletier, D.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA.
Document URI:	http://hdl.handle.net/1942/27409
ISSN:	1351-5101
e-ISSN:	1468-1331
ISI #:	000435272002408
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
p 527 2018-European_Journal_of_Neurology.pdf	Published version	104.31 kB	Adobe PDF	View/Open

10

checked on Sep 7, 2022

2

checked on Sep 7, 2022

Check